Dr. Tim-Henrik Bruun
Co-Founder
Manager of the NVP-13 team with 8 years of operational and research experience.
career
| 2011-2019 | "CampoNeuro" NVP-13 grant Project Manager for (grants: BioM, ZIM, GO-Bio), Regensburg | |
| 2006-2011 | Postdoc in the Field of HIV-Vaccine Discovery with Prof. R. Wagner at the University Hospital Regensburg | |
| 2005-2006 | Screening and Selection of Monoclonal Antibody Fragments using Phage Display Technology with Prof. S. Dübel at TU-Braunschweig | |
Publications
Peters, S.; Zitzelsperger, E.; Kuespert, S.; Iberl, S.; Heydn, R.; Johannesen, S.; Petri, S.; Aigner, L.; Thal, D.R.; Hermann, A.; et al. The TGF-β System As a Potential Pathogenic Player in Disease Modulation of Amyotrophic Lateral Sclerosis. Frontiers in neurology 2017, 8, 669, doi:10.3389/fneur.2017.00669.
Peters, S.; Kuespert, S.; Wirkert, E.; Heydn, R.; Jurek, B.; Johannesen, S.; Hsam, O.; Korte, S.; Ludwig, F.; Mecklenburg, L.; et al. Reconditioning the Neurogenic Niche of Adult Non-human Primates by Antisense Oligonucleotide-Mediated Attenuation of TGFβ Signaling. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2021, doi:10.1007/s13311-021-01045-2.
Peters, S.; Wirkert, E.; Kuespert, S.; Heydn, R.; Johannesen, S.; Friedrich, A.; Mailänder, S.; Korte, S.; Mecklenburg, L.; Aigner, L.; et al. Safe and Effective Cynomolgus Monkey GLP-Tox Study with Repetitive Intrathecal Application of a TGFBR2 Targeting LNA-Gapmer Antisense Oligonucleotide as Treatment Candidate for Neurodegenerative Disorders. Pharmaceutics 2022, 14, doi:10.3390/pharmaceutics14010200.
Kozole, J.; Heydn, R.; Wirkert, E.; Küspert, S.; Aigner, L.; Bruun, T.-H.; Bogdahn, U.; Peters, S.; Johannesen, S. Direct Potential Modulation of Neurogenic Differentiation Markers by Granulocyte-Colony Stimulating Factor (G-CSF) in the Rodent Brain. Pharmaceutics 2022, 14, doi:10.3390/pharmaceutics14091858.
Peters, S.; Wirkert, E.; Kuespert, S.; Heydn, R.; Korte, S.; Mecklenburg, L.; Aigner, L.; Johannesen, S.; Bruun, T.-H.; Bogdahn, U. Targeting TGF-ß in the Central Nervous System: Assessment of Cynomolgus Monkey—Toxicity and Pharmacokinetics for an LNA-Antisense Oligonucleotide. Applied Sciences 2022, doi:https://doi.org/10.3390/app12030973.
Kuespert, S.; Heydn, R.; Peters, S.; Wirkert, E.; Meyer, A.-L.; Siebörger, M.; Johannesen, S.; Aigner, L.; Bogdahn, U.; Bruun, T.-H. Antisense Oligonucleotide in LNA-Gapmer Design Targeting TGFBR2-A Key Single Gene Target for Safe and Effective Inhibition of TGFβ Signaling. International journal of molecular sciences 2020, 21, doi:10.3390/ijms21061952.
Wirth, A.M.; Johannesen, S.; Khomenko, A.; Baldaranov, D.; Bruun, T.-H.; Wendl, C.; Schuierer, G.; Greenlee, M.W.; Bogdahn, U. Value of fluid-attenuated inversion recovery MRI data analyzed by the lesion segmentation toolbox in amyotrophic lateral sclerosis. Journal of magnetic resonance imaging : JMRI 2019, 50, 552-559, doi:10.1002/jmri.26577.
Wirth, A.M.; Khomenko, A.; Baldaranov, D.; Kobor, I.; Hsam, O.; Grimm, T.; Johannesen, S.; Bruun, T.-H.; Schulte-Mattler, W.; Greenlee, M.W.; et al. Combinatory Biomarker Use of Cortical Thickness, MUNIX, and ALSFRS-R at Baseline and in Longitudinal Courses of Individual Patients With Amyotrophic Lateral Sclerosis. Frontiers in neurology 2018, 9, 614, doi:10.3389/fneur.2018.00614.
Johannesen, S.; Budeus, B.; Peters, S.; Iberl, S.; Meyer, A.-L.; Kammermaier, T.; Wirkert, E.; Bruun, T.-H.; Samara, V.C.; Schulte-Mattler, W.; et al. Biomarker Supervised G-CSF (Filgrastim) Response in ALS Patients. Frontiers in neurology 2018, 9, 971, doi:10.3389/fneur.2018.00971.
